January Newsletter
Eli Lilly Canada Inc. announced today that OLUMIANT (baricitinib) received regulatory approval for its severe alopecia areata indication via Notice of Compliance (NOC) from Health Canada.
Navigate with Confidence: Mental Health Resources Resources Music & Wellbeing Handbook